Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years and need complete bladder excision. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate feasibility, safety and therapeutic efficacy of the α-emitter radioimmunoconjugate in recurrent bladder cancer patients.
SCHEIDHAUER Klemens;
SEIDL C.;
BRUCHERTSEIFER Frank;
APOSTOLIDIS Christos;
AUTENRIETH M.;
KURTZ F;
HORN Thomas;
SCHWAIGER M.;
GSCHWEND J.E.;
D’ALESSANDRIA Calo;
PFOB C;
SENEKOWITSCH-SCHMIDTKE R.;
MORGENSTERN Alfred;
2017-10-25
SPRINGER
JRC106724
1619-7070,
https://link.springer.com/journal/259/44/2/suppl/page/1,
https://publications.jrc.ec.europa.eu/repository/handle/JRC106724,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|